Sacrococcygeal teratoma (SCT) is a rare tumor that develops at the base of the tailbone (coccyx) in infants. It is the most common tumor found in newborns, with an estimated prevalence of approximately 1 in every 35,000 to 40,000 live births. SCTs are more commonly diagnosed in females, with a female-to-male ratio of about 4:1.
These tumors are typically detected during routine prenatal ultrasounds or shortly after birth. The size and characteristics of SCTs can vary significantly, ranging from small, benign masses to large, complex tumors with malignant potential. The majority of SCTs are benign, but a small percentage can be cancerous.
Early diagnosis and appropriate management are crucial for the best outcomes. Treatment options for SCTs include surgical removal of the tumor, which may involve a multidisciplinary team of specialists. The prognosis for infants with SCTs is generally favorable, with a high survival rate. However, the long-term outcomes can be influenced by factors such as tumor size, location, and potential complications.
Overall, while sacrococcygeal teratomas are relatively rare, they require prompt medical attention and specialized care to ensure the best possible outcome for affected infants.